ProAxsis appoints Dr David Ribeiro as CEO
Date : October 01, 2015
Dr Ribeiro will join the Group on 1 October 2015 to oversee the ongoing development of ProAxsis’ diagnostic portfolio. He has extensive experience in commercialising products within chronic diseases, having previously held senior management roles at Solvay Healthcare, Encysive Pharmaceuticals and Pfizer. Most recently, David held the role of European Business Manager at Pharmaxis Pharmaceuticals Limited, a Sydney-based company with two launched products – a diagnostic test for assessing bronchial hyper-responsiveness in asthma, and a therapeutic product designed for the chronic treatment of patients with Cystic Fibrosis.
Dr Lorraine Martin (ProAxsis founding CEO) will become CTO focusing on technical operations with co-founder Professor Brian Walker retaining his position as CSO.
François R. Martelet, M.D., Group CEO of NetScientific, commented: “ProAxsis is in the early stages of its commercialisation strategy of its ProteaseTag™ immunoassay kits. The company is also developing its NEATstik™ device for the much larger point-of-care market. We want to further drive these commercialisation and development programmes, and therefore, finding the right CEO to lead this has been very important. David has a strong reputation in commercialising diagnostic products and has extensive contacts within the industry. We welcome him to the team.”
Dr David Ribeiro commented: “ProAxsis is at an exciting phase of its development as the first output of its extensive pipeline moves into commercialisation. My role as CEO will be to drive the business forward to ensure availability and rapid uptake of each of the company’s products into multiple markets across the world. In my view, the ProAxsis team comprise the perfect combination of scientific excellence and product development. I anticipate a continuing stream of novel diagnostic products that will present real advances in the management of numerous patients diagnosed with chronic diseases.”
ProAxsis is a point of care diagnostic products company. It is developing a range of products for the capture, detection and measurement of active protease biomarkers of diseases using its proprietary Protease Tag technology. The company’s lead product measures Neutrophil Elastase, a leading indicator of infection in patients with Cystic Fibrosis (CF) and Chronic Obstructive Pulmonary Disease (COPD), and is an important drug target. ProAxsis launched its first‐in‐class active neutrophil elastase immunoassay kit for the research market in August 2015.
ProAxsis is also developing a point-of-care (PoC) NEATstik™ test to measure active proteases in CF and COPD which will enable the proactive management of these diseases with the aim of improving patient outcome and reducing hospitalisations. NEATstik™ will enable entry into the rapidly growing PoC market that is estimated to be worth over £20 billion. The test has the potential to revolutionise the management of respiratory diseases, acting as an early monitoring device for patients to alert them of a potential infection.
ProAxsis was named one of Northern Ireland's most promising companies in 2013. It is also the only company in Northern Ireland, and one of only a few in the UK, to have secured a prestigious Horizon 2020 SME Instrument Award. For more information, please visit: www.proaxsis.com